The human gastrointestinal tract is a complex ecosystem where specific microbial taxa play disproportionate roles in maintaining metabolic and immunological homeostasis. Among these, the genus Anaerobutyricum has emerged as a focal point in the development of Next-Generation Probiotics (NGPs) and Live Biotherapeutic Products (LBPs). Recent scientific synthesis highlights this genus, particularly A. hallii and A. soehngenii, as key drivers of butyrate production through unique metabolic pathways. As the industry shifts from general probiotics to targeted microbial therapies, understanding the physiological requirements and therapeutic potential of Anaerobutyricum is paramount. At Creative Biolabs, we bridge the gap between academic discovery and commercial realization, providing the technical infrastructure necessary to translate Anaerobutyricum research into viable clinical candidates. Consult Our Scientists for Your LBP Project.
Overview: Characterization of the Emerging Genus Anaerobutyricum1
The genus Anaerobutyricum was recently delineated to accommodate species formerly classified under Eubacterium hallii. This reclassification, based on polyphasic taxonomy including 16S rRNA gene sequencing and phylogenomic analysis, identifies these organisms as Gram-positive, anaerobic, non-spore-forming, catalase-negative, and slightly curved rod-shaped bacteria. They are members of the Lachnospiraceae family within the Phylum Bacillota.
Core Metabolic Pathways and Mechanism of Action
The scientific primary focus on Anaerobutyricum centers on its role as a metabolic consumer of lactic acid and acetic acid, which it converts into butyric acid (butyrate). Unlike other classical butyrate producers that utilize complex polysaccharides, Anaerobutyricum relies heavily on the utilization of metabolic intermediates generated by primary degraders (such as Bifidobacterium spp.).
-
Lactate and Acetate Clearance: The genus utilizes a functional butyryl-CoA:acetate CoA-transferase pathway to process exogenous acetate and lactate, thereby preventing the toxic accumulation of lactic acid in the intestinal lumen, which can lead to metabolic acidosis and mucosal irritation.
-
Butyrate Biosynthesis: The quantitative synthesis of butyrate by Anaerobutyricum serves as the primary energy substrate for colonocytes, promoting tight junction protein expression (e.g., zonula occludens-1, claudin-1), mitigating inflammatory cascades via NF-κB inhibition, and inducing regulatory T cell (Treg) differentiation.
The researchers conclude that Anaerobutyricum represents a significant functional component of the gut microbiota. Its ability to convert lactate into butyrate not only supports colonocyte health but also influences systemic metabolic markers, making it a primary candidate for LBP development targeting metabolic and inflammatory disorders.
Advanced Preclinical CRO Services to Accelerate Anaerobutyricum Research
Translating the complex biology of Anaerobutyricum into a standardized therapeutic product requires a highly specialized experimental framework. Based on the experimental pathways described in the literature, Creative Biolabs offers the following matched CRO services:
Utilizing advanced anaerobic workstations, we offer custom isolation, purification, and scale-up cultivation of strictly anaerobic strains from diverse biological matrices.
To evaluate cross-feeding and SCFA production, our analytical platform utilizes validated HPLC and GC-MS workflows to precisely quantify butyrate, acetate, propionate, lactate, and branched-chain fatty acids in vitro and ex vivo.
Genomic and Bioinformatic Analysis
We provide high-throughput Next-Generation Sequencing (NGP/LBP sequencing), whole-genome sequencing (WGS), and bioinformatic pipelines to identify functional gene clusters, such as the butyryl-CoA:acetate CoA-transferase pathway, and safety-related traits including antibiotic resistance genes (ARGs) and virulence factors.
Our platform supports co-culture models, intestinal organoid evaluations, and Caco-2 monolayer assays to measure epithelial tight-junction integrity (TEER measurements) and anti-inflammatory cytokine modulation (IL-10, TNF-alpha, IL-6) in response to bacterial treatments.
We feature fully validated animal models to evaluate the therapeutic efficacy of Anaerobutyricum candidates, including diet-induced obesity models, streptozotocin (STZ)-induced diabetes models, and dextran sulfate sodium (DSS)-induced colitis models.
Scientific Products Supporting Anaerobutyricum Research
To accelerate your R&D timeline, Creative Biolabs provides a suite of commercial products specifically matched to the study of butyrate-producing anaerobes:
-
Microbial Strains: We offer various Anaerobic Bacteria Type Strains within the Lachnospiraceae family to serve as reference controls for your comparative studies.
-
Anaerobutyricum hallii Genomic DNA: High-molecular-weight DNA extracted from authenticated strains, ideal for whole-genome sequencing libraries or metagenomic comparative studies.
-
Anaerobutyricum hallii DNA Standard: A precision-quantified standard for use in qPCR or digital PCR (dPCR) assays to determine the absolute abundance of A. hallii in clinical or environmental samples.
-
Eubacterium hallii derived Extracellular Vesicles (EVs): Purified EVs to facilitate research into the host-microbe "secretome." These products are essential for studying how Anaerobutyricum communicates with host immune and endocrine cells independently of the live bacteria.
-
Heat inactivated Anaerobutyricum hallii: Standardized heat-killed cells (Postbiotics) used as controls in immunological assays or for evaluating the efficacy of non-viable microbial components in metabolic regulation.
Platform Advantages: Excellence in Anaerobic LBP Development
Creative Biolabs maintains a leading position in the LBP field by providing specialized infrastructure tailored for the Lachnospiraceae family:
Stringent Anaerobic Control
Our platform operates within integrated anaerobic workstations and closed-system bioreactors, ensuring that even the most oxygen-sensitive Anaerobutyricum strains remain viable and metabolically active.
Translational Expertise
We bridge the gap between basic microbiology and pharmaceutical science, offering stability testing, lyophilization optimization, and encapsulation services for anaerobic strains.
Data-Driven Customization
We do not offer "one-size-fits-all" solutions. Every project is designed based on the specific metabolic requirements of the client's strain, utilizing the latest findings from literature like the Anaerobutyricum genus review.
Application Fields of Anaerobutyricum Research
-
Metabolic Syndrome & Type 2 Diabetes: Developing LBPs that restore insulin sensitivity through SCFA-mediated pathways.
-
Inflammatory Bowel Disease (IBD): Utilizing butyrate-producing strains to strengthen the intestinal barrier and reduce mucosal inflammation.
-
Postbiotic Therapeutics: Utilizing heat-inactivated strains or EVs for targeted delivery of microbial signals in patients where live bacteria may be contraindicated.
-
Metagenomic Diagnostics: Developing biomarkers based on Anaerobutyricum abundance to predict the risk of metabolic decline.
Partnering for Clinical Discovery
The emerging data surrounding Anaerobutyricum emphasizes its distinct position within the intestinal microbiome as a metabolic cross-feeder capable of turning organic acids into beneficial butyrate. Fully exploiting this genus for therapeutic or commercial development demands meticulous validation across strain isolation, metabolic evaluation, and in vivo disease modeling. Creative Biolabs acts as a specialized technical partner, offering the precise anaerobic infrastructure, analytical workflows, and pre-characterized strain portfolios required to de-risk your LBP discovery pipeline.
To discuss your specific experimental design, request a technical consultation, or receive a formal quote for our Anaerobutyricum research services and products, please contact our scientific team via our official inquiry portal.
Frequently Asked Questions (FAQs)
What are the primary technical challenges when cultivating Anaerobutyricum strains in vitro?
Anaerobutyricum is an obligate anaerobe that is highly sensitive to oxygen exposure. Cultivation requires strictly maintained anaerobic gases and specialized media formulations supplemented with appropriate acetate and lactate donors to support growth and metabolic cross-feeding behaviors.
How does Anaerobutyricum differ from Faecalibacterium prausnitzii in terms of butyrate production?
While both are prominent butyrate producers, Faecalibacterium prausnitzii typically relies on the consumption of specific dietary fibers and acetate. In contrast, Anaerobutyricum possesses the specialized enzymatic machinery to efficiently clear lactate and convert it, alongside acetate, into butyrate, representing a distinct metabolic niche that helps mitigate localized lactic acidosis.
Can your platform assist in safety assessments required for regulatory LBP filings?
Yes. Creative Biolabs provides comprehensive safety qualification packages, including complete genomic sequencing for phenotypic antibiotic resistance profiling, mobile genetic element screening, in vitro hemolysis assays, and acute/chronic toxicity studies in animal models according to international regulatory frameworks.
How do you differentiate between Anaerobutyricum hallii and A. soehngenii in a mixed sample?
We utilize high-resolution phylogenomic analysis and specific primer sets targeting unique regions identified through our WGS services. This allows for precise quantification of species-level abundance within the genus.
What are the advantages of using E. hallii-derived Extracellular Vesicles (EVs) in research?
EVs contain proteins, lipids, and nucleic acids that can cross the mucus layer and interact directly with host cells. They are increasingly used to study the non-metabolic mechanisms by which Anaerobutyricum influences host physiology without the risks associated with live bacterial translocation.
Reference
-
Yan, Chunyu, and Mengqing Zhou. "Anaerobutyricum-An Emerging Butyrate-Producing Genus with Potential Relevance to Host Health." Microorganisms 14,6 1304. 10 Jun. 2026, doi:10.3390/microorganisms14061304. Distributed under Open Access license CC BY 4.0, without modification.
